Mark Elliott Boulding, who serves as Executive Vice President and Chief Legal Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), executed a series of stock transactions on June 17, 2026, according to a recent Securities and Exchange Commission (SEC) filing.
The filing details that Mr. Boulding sold a total of 10,462 shares of PTC Therapeutics common stock. This transaction resulted in realized proceeds of approximately $822,867. The sales were executed at prices ranging from $78.00 to $79.49 per share. The timing of this activity is notable, as the stock currently trades at $81.03, which is near its 52-week high of $87.50. The stock has experienced a strong 57% gain over the past year.
According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive analysis through the company’s Pro Research Report, available for PTCT and 1,400+ US equities.
Concurrently with the sale, Mr. Boulding acquired 10,522 shares of common stock by exercising stock options. These shares were acquired at a price of $46.54 per share, amounting to approximately $489,693. The stock options exercised were granted on January 3, 2025, and vest over a four-year period.
All reported transactions were carried out pursuant to a Rule 10b5-1 trading plan, which Mr. Boulding adopted on September 10, 2025. Following these transactions, Mr. Boulding directly holds 105,272 shares of PTC Therapeutics common stock.
In other recent news, PTC Therapeutics reported strong earnings for the first quarter of 2026, surpassing analyst expectations. The company posted an earnings per share (EPS) of -$0.03, significantly better than the forecasted -$0.46. The company also reported revenues of $273 million, exceeding the anticipated $224.08 million.
Meanwhile, Jefferies upgraded PTC Therapeutics to a Buy rating, raising its price target to $85, citing positive expectations for the Sephience product. BofA Securities maintained its Buy rating with a $93 price target, highlighting the momentum of the Sephience launch and the company’s strategy discussed with CEO Dr. Matthew Klein. TD Cowen also upgraded the stock to Buy, increasing the price target to $90, due to the company’s operational improvements and the early success of a new product launch.
These developments reflect a growing confidence in PTC Therapeutics’ financial performance and strategic direction.